The main clinical symptom score in Potassium alginate group was significantly lower than that before the test and that in control group(P< 0.05).
海藻酸钾试食组主要临床症状积分降低，与安慰剂对照组及试食前比较差异有统计学意义（P<0.05）。
The total effective rate of clinical symptoms by Potassium alginate was 76.47%.
海藻酸钾试食组临床症状改善总有效率为76.47%。
Conclusion The efficacy and safety of potassium alginate for hypertension was similar to indapamide.
结论海藻酸钾散剂与寿比山具有相似的降压疗效，是一种安全、有效的降压药。
Objective To observe the effect of potassium alginate (PA) on absorption of lipids, the level of blood lipid and deposit of fat.
目的观察褐藻酸钾(PA)对脂类吸收、血脂水平、脂肪存贮的影响。
Objective:To study the efficacy and safety of Potassium Alginate in assisting antihypertensive drugs lowering blood pressure of primary hypertension patients.
目的：研究海藻酸钾辅助降压药物降低原发性高血压病患者血压的效果及安全性。
Objective:To study the efficacy and safety of Potassium Alginate in assisting antihypertensive drugs lowering blood pressure of primary hypertension patients.
目的：研究海藻酸钾辅助降压药物降低原发性高血压病患者血压的效果及安全性。
应用推荐